Status:

UNKNOWN

Oral Helicobacter Pylori Eradication

Lead Sponsor:

Changhai Hospital

Conditions:

H. Pylori Infection

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

Helicobacter pylori (H. pylori) is a serious health threat that infects approximately half of the global population. In addition to colonizing the stomach, H. pylori has been shown to survive in the o...

Detailed Description

Inclusion criteria: oral H. pylori-positive patients, verified by H. pylori saliva test (HPS),aged 18-70 years visiting the outpatient clinic of Changhai Hospital from March 1, 2023, to August 1, 2023...

Eligibility Criteria

Inclusion

  • Oral H. pylori-positive patients, verified by H. pylori saliva test (HPS),aged 18-70 years visiting the outpatient clinic of Changhai Hospital from March 1, 2023, to August 1, 2023, were enrolled.

Exclusion

  • (1) Zollinger-Ellison syndrome, gastric cancer, upper gastrointestinal bleeding, or active peptic ulcer; (2) the coexistence of significant concomitant illnesses, including heart diseases, renal failure, hepatic disease, previous abdominal surgery, lactation or pregnancy; and (3) not willing to participate in the study.
  • \-

Key Trial Info

Start Date :

March 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 30 2023

Estimated Enrollment :

42 Patients enrolled

Trial Details

Trial ID

NCT06045832

Start Date

March 1 2023

End Date

September 30 2023

Last Update

September 21 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Changhai hospital

Shanghai, Shanghai Municipality, China, 200433